Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors

Wei Xie; Sa A. Wang; Shimin Hu; Jie Xu; L. Jeffrey Medeiros; Guilin Tang

doi:10.1016/j.cancergen.2018.08.002

Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors

Wei Xie, Sa A. Wang, Shimin Hu, Jie Xu, L. Jeffrey Medeiros, Guilin Tang

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.

Original language	English (US)
Pages (from-to)	41-46
Number of pages	6
Journal	Cancer Genetics
Volume	228-229
DOIs	https://doi.org/10.1016/j.cancergen.2018.08.002
State	Published - Dec 2018
Externally published	Yes

Keywords

ABL1-ETV6 rearrangement
Myeloproliferative neoplasm
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1016/j.cancergen.2018.08.002

Cite this

@article{d1d312e20c724aa9b760150b90cb5187,

title = "Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors",

abstract = "Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.",

keywords = "ABL1-ETV6 rearrangement, Myeloproliferative neoplasm, Tyrosine kinase inhibitors",

author = "Wei Xie and Wang, {Sa A.} and Shimin Hu and Jie Xu and Medeiros, {L. Jeffrey} and Guilin Tang",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = dec,

doi = "10.1016/j.cancergen.2018.08.002",

language = "English (US)",

volume = "228-229",

pages = "41--46",

journal = "Cancer Genetics",

issn = "2210-7762",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors

AU - Xie, Wei

AU - Wang, Sa A.

AU - Hu, Shimin

AU - Xu, Jie

AU - Medeiros, L. Jeffrey

AU - Tang, Guilin

PY - 2018/12

Y1 - 2018/12

N2 - Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.

AB - Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.

KW - ABL1-ETV6 rearrangement

KW - Myeloproliferative neoplasm

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85053789023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053789023&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2018.08.002

DO - 10.1016/j.cancergen.2018.08.002

M3 - Article

C2 - 30553471

AN - SCOPUS:85053789023

SN - 2210-7762

VL - 228-229

SP - 41

EP - 46

JO - Cancer Genetics

JF - Cancer Genetics

ER -

Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this